This article is an erratum on:
Case Report: VEXAS Syndrome: From Mild Symptoms to Life-Threatening Macrophage Activation Syndrome
Frontiers Production Office*An Erratum on:
Case Report: VEXAS Syndrome: From Mild Symptoms to Life-Threatening Macrophage Activation Syndrome
Staels F, Betrains A, Woei-A-Jin FJSH, Boeckx N, Beckers M, Bervoets A, Willemsen M, Neerinckx B, Humblet-Baron S, Blockmans DE, Vanderschueren S and Schrijvers R (2021). Front. Immunol. 12:678927. doi: 10.3389/fimmu.2021.678927
Due to a production error, an author name was incorrectly written as “Sherida Woei-A-Jin”, which did not match the citation. The correct name is “F J Sherida H Woei-A-Jin”. The publisher apologizes for this mistake.
The original version of this article has been updated.
Keywords: primary immunodeficiencies, autoinflammation, treatment reactions, myelodysplasia, ubiquitination
Citation: Frontiers Production Office (2021) Erratum: Case Report: VEXAS Syndrome: From Mild Symptoms to Life-Threatening Macrophage Activation Syndrome. Front. Immunol. 12:748756. doi: 10.3389/fimmu.2021.748756
Received: 28 July 2021; Accepted: 28 July 2021;
Published: 10 August 2021.
Copyright © 2021 Frontiers Production Office. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Frontiers Production Office, production.office@frontiersin.org